Purpose: To investigate the effect of subconjunctival bevacizumab immediately after excision of primary pterygium.
Methods: Eighty patients (80 eyes) with primary pterygium were included in this double-blind clinical trial. The pterygia were excised by the bare sclera technique. Then, the patients were randomized in 2 equal groups; group A received subconjunctival bevacizumab (1.25 mg/0.1 mL) injected immediately after surgical excision of the pterygium, and placebo was administered in the same way in group B. Patients were followed-up for 9 months after the operation, and the possible complications and recurrence rate were documented. Thirty-three patients (33 eyes) completed the study in each group.
Results: The rate of complications was comparable between the 2 groups (57.6% in group A versus 63.6% in group B; P = 0.61). None of these complications was clinically significant, and they resolved spontaneously or by using conservative measures. The recurrence rate was higher in group B compared with group A (57.6% vs. 45.5%); however, this difference was not statistically significant (P = 0.33; odds ratio, 1.63; 95% confidence interval, 0.62-4.31).
Conclusions: Subconjunctival injection of bevacizumab immediately after surgical excision of primary pterygium is well-tolerated, but it cannot significantly prevent the recurrence of this condition.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/ICO.0b013e31820ca63f | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Subconjunctival injection of anti-VEGF agent bevacizumab as treatment in patients with dry eye disease.
Pak J Pharm Sci
September 2024
LRBT, Eye Hospital, Korangi, Pakistan.
To assess the effect of subconjunctival injection of anti-VEGF bevacizumab in the management of dry eye disease in a tertiary care hospital. In this quasi-experimental trial 150 eyes of 75 patients were selected using non-probability consecutive sampling technique. Detailed clinical examination was performed, the ocular surface disease index (OSDI) questionnaire score, tear film break-up time (TBUT) and Schirmer test 2 were measured and compared pre and post injection.
View Article and Find Full Text PDF[A randomized study of subconjonctival bevacizumab (Avastin®) injection for corneal neovascularization].
J Fr Ophtalmol
April 2024
CHU Dupuytren, 2, avenue Martin-Luther-King, 87042 Limoges cedex, France. Electronic address:
Purpose: The goal of this phase III, comparative, multicentric, randomized, double-blinded clinical trial was to investigate the superiority of subconjunctival bevacizumab injections versus placebo in the treatment of corneal neovascularization.
Patients And Methods: We included 38 eyes (38 patients) with corneal neovascularization. Twenty patients received bevacizumab and 18 placebos.
Suppression of Neovascularization by Topical and Subconjunctival Bevacizumab After High-Risk Corneal Transplantation.
Ophthalmol Sci
February 2024
Cornea Service, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts.
Purpose: To assess the effectiveness of topical and subconjunctival bevacizumab in suppressing vascularization in graft and host bed after high-risk corneal transplantation.
Design: Secondary analysis of prospective, randomized, double-blind, placebo-controlled multicentric clinical trial.
Participants: The study includes patients aged > 18 years who underwent high-risk penetrating keratoplasty, which was defined as corneal vascularization in ≥ 1 quadrants of the corneal graft and host bed, excluding the limbus.
Comparison of photodynamic therapy with two different parameters combined with subconjunctival injection of bevacizumab for corneal neovascularization.
Photodiagnosis Photodyn Ther
April 2024
The State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center at Sun Yat-sen University, Guangzhou 510060, China. Electronic address:
Article Synopsis
- - This study aimed to assess the effectiveness of two different photodynamic therapy (PDT) protocols combined with the drug bevacizumab for treating corneal neovascularization (CNV) in patients unresponsive to conventional treatments.
- - Patients were divided into two groups: one received lower energy PDT parameters, while the other received higher energy parameters, with the bevacizumab injection given immediately after PDT.
- - Results showed that overall, 60% of patients experienced improved vision and there was a significant reduction in neovascularization, particularly in the group that received the higher energy treatment, demonstrating the potential of optimized combined therapy for CNV.
Mitomycin intravascular chemoembolization (MICE) to treat corneal vascularization prior to penetrating keratoplasty.
Am J Ophthalmol Case Rep
March 2024
Department of Ophthalmology, Dean McGee Eye Institute, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Purpose: To present the clinical outcome of mitomycin intravascular chemoembolization (MICE) as a prophylactic treatment in a patient with HSV-induced corneal neovascularization (NV) before penetrating keratoplasty (PKP).
Observations: A 53-year-old male patient presented with a medical history of recurrent herpes simplex virus (HSV) corneal infection. The patient reported worsening visual acuity despite maintenance treatment with systemic antivirals and topical corticosteroids.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!